8-K: Lifeward Secures $1.5M High-Interest Debt from Oramed

Lifeward Ltd. entered into a new secured promissory note with Oramed Pharmaceuticals, Inc. for up to $1.5 million at a 24% annual interest rate, secured by the company's cash.

Summary

• Lifeward Ltd. entered into a Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. on February 12, 2026.
• The note has an initial principal of $525,000, with an option to increase by an additional $975,000, totaling up to $1.5 million.
• It accrues interest at a high rate of 24% per annum.
• The note is secured by a lien on the Company's cash.
• Maturity is the earlier of August 12, 2026, or failure to obtain shareholder approval for related transactions from January 12, 2026.
• An Initial Secured Promissory Note of $3.0 million with Oramed Ltd. remains outstanding, and collateral proceeds will be applied ratably to both notes.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development due to the extremely high interest rate, the cash collateral, and the short-term, conditional nature of the financing, all pointing to severe financial strain.

Positives

• Secured additional funding of up to $1.5 million, providing short-term liquidity.

Negatives

• The promissory note carries a very high interest rate of 24% per annum.
• The note is secured by a lien on the Company's cash, limiting financial flexibility.
• Maturity is accelerated if shareholder approval for related transactions is not obtained.
• The company already has an outstanding $3.0 million secured promissory note with Oramed Ltd.

Risks

• Failure to obtain shareholder approval for the transactions contemplated by the Securities Purchase Agreement and Share Purchase Agreement (dated January 12, 2026) will trigger early maturity of the note.
• The high interest rate of 24% per annum increases the cost of capital and financial burden.
• The lien on the Company's cash restricts its ability to use these funds for other operational needs.
• Customary events of default, including non-payment, covenant breaches, insolvency, bankruptcy, or a material adverse effect, could lead to acceleration of payment and other remedies by Oramed.
• The company's ability to repay the combined $4.5 million in secured debt (initial $3.0M + subsequent $1.5M) by August 2026 is a significant concern.

Future Outlook

The filing indicates that the company needs to obtain shareholder approval for transactions contemplated by the Securities Purchase Agreement and Share Purchase Agreement, dated January 12, 2026, by specific outside dates, as failure to do so will accelerate the maturity of the new promissory note.

Management Comments

• "The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Subsequent Secured Promissory Note, a copy of which will be filed as an exhibit to the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2025."

Industry Context

StockSavvy.ai notes that securing debt at a 24% interest rate, especially when collateralized by cash, typically signals significant financial distress or a high-risk profile for a company, often seen in early-stage ventures or those facing liquidity challenges. This type of financing is far from standard for established public companies and suggests limited access to conventional credit markets.

Comparison to Industry Standards

• The 24% annual interest rate is substantially higher than typical corporate borrowing rates, which for companies with stable financials usually range from 5-10% for secured debt, even for smaller or mid-cap firms.
• Securing a loan with a lien on the company's cash is an aggressive measure, indicating a lender's strong demand for security and a company's limited alternative collateral, unlike standard corporate loans often secured by broader asset classes or receivables.
• The short maturity period (August 2026) and the condition tied to shareholder approval for other transactions are indicative of bridge financing under urgent circumstances, rather than long-term strategic capital.
• Comparable companies in a healthier financial position would typically access revolving credit facilities or term loans from commercial banks at much lower rates (e.g., 3-8% depending on credit rating) or issue convertible notes with more favorable terms.

Related Party Transactions

• Lifeward Ltd. entered into the Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc.
• Lifeward Ltd. previously entered into an Initial Secured Promissory Note with Oramed Ltd. for $3.0 million, which remains outstanding.
• The filing mentions "transactions with affiliates" in the covenants, suggesting Oramed is considered an affiliate.

Stakeholder Impact

• Shareholders face increased financial risk due to high-interest debt and potential dilution or further unfavorable financing if the company cannot meet its obligations or secure better terms. The need for shareholder approval for related transactions also impacts them directly.
• Oramed, as a secured creditor, has a lien on the company's cash, giving it priority over unsecured creditors. Other creditors may face higher risk.
• Employees, customers, and suppliers may experience potential impact on operational stability and long-term viability if the company's financial health deteriorates further due to high debt servicing costs.

Next Steps

• Obtain shareholder approval for the transactions contemplated by the Securities Purchase Agreement and Share Purchase Agreement (dated January 12, 2026) by their respective outside dates.
• File the full text of the Subsequent Secured Promissory Note as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

Key Dates

Recommendation

The company is taking on debt at an exorbitant 24% interest rate, secured by its cash, which is a clear indicator of severe financial distress and limited access to conventional capital. This, coupled with an existing $3.0 million secured note from a related party and the short maturity tied to shareholder approval, suggests a precarious financial position. The high cost of capital will significantly erode future profitability and raises serious concerns about the company's ability to meet its obligations, making the stock a strong sell.

Keywords

Lifeward Ltd., LFWD, Oramed Pharmaceuticals, Secured Promissory Note, Debt Financing, High Interest Debt, Shareholder Approval, Cash Lien, Corporate Finance, SEC Filing, 8-K